The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Abstract
Purpose: Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations—including ASXL1—have been associated with poor prognosis in univariable analyses. We developed and validated a prognostic score for overall survival (OS) based on mutational status and standard clinical variables. Patients and Methods: We genotyped ASXL1 and up to 18 other genes including epigenetic (TET2, EZH2, IDH1, IDH2, DNMT3A), splicing (SF3B1, SRSF2, ZRSF2, U2AF1), transcription (RUNX1, NPM1, TP53), and signaling (NRAS, KRAS, CBL, JAK2, FLT3) regulators in 312 patients with CMML. Genotypes and clinical variables were included in a multivariable Cox model of OS validated by bootstrapping. A scoring system was developed using regression coefficients from this model. Results: ASXL1 mutations (P < .0001) and, to a lesser extent, SRSF2 (P = .03), CBL (P = .003), and IDH2 (P = .03) mutations predicted inferior OS in univariable analysis. The retained independent prognostic factors included ASXL1 mutations, age older than 65 years, WBC count greater than 15 ×10 9 /L, platelet count less than 100 ×10 9 /L, and anemia (hemoglobin < 10 g/dL in female patients, < 11g/dL in male patients). The resulting five-parameter prognostic score delineated three groups of patients with median OS not reached, 38.5 months, and 14.4 months, respectively (P < .0001), and was validated in an independent cohort of 165 patients (P < .0001). Conclusion: A new prognostic score including ASXL1 status, age, hemoglobin, WBC, and platelet counts defines three groups of CMML patients with distinct outcomes. Based on concordance analysis, this score appears more discriminative than those based solely on clinical parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationVardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Self-citationFrequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
Self-citationPrognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Self-citationQuivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
Self-citationGenetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-210039 · Cited by 727
Li, Z., Cai, X., Cai, C.-L., Wang, J., Zhang, W., Petersen, B. E., Yang, F.-C., & Xu, M. (2011) · Blood · doi:10.1182/blood-2010-12-325241 · Cited by 671
Ko, M., Bandukwala, H. S., An, J., Lamperti, E. D., Thompson, E. C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S. B., & Rao, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112317108 · Cited by 616
ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Abdel-Wahab, O., Adli, M., LaFave, L. M., Gao, J., Hricik, T., Shih, A. H., Pandey, S., Patel, J. P., Chung, Y. R., Koche, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.032 · Cited by 599
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07697.x · Cited by 564
Self-citationKantarjian, H., O'Brien, S., Ravandi, F., Cortes, J., Shan, J., Bennett, J. M., List, A., Fenaux, P., Sanz, G., Issa, J., et al. (2008) · Cancer · doi:10.1002/cncr.23697 · Cited by 482
Self-citationBejar, R., Stevenson, K. E., Caughey, B. A., Abdel-Wahab, O., Steensma, D. P., Galili, N., Raza, A., Kantarjian, H., Levine, R. L., Neuberg, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7379 · Cited by 441
New mutations and pathogenesis of myeloproliferative neoplasms
Vainchenker, W., Delhommeau, F., Constantinescu, S. N., & Bernard, O. A. (2011) · Blood · doi:10.1182/blood-2011-02-292102 · Cited by 395
Self-citationOnida, F., Kantarjian, H. M., Smith, T. L., Ball, G., Keating, M. J., Estey, E. H., Glassman, A. B., Albitar, M., Kwari, M. I., & Beran, M. (2002) · Blood · doi:10.1182/blood.v99.3.840 · Cited by 385
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A. M., Abu Kar, S., Jerez, A., Przychodzen, B., Bupathi, M., Guinta, K., Afable, M. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399774 · Cited by 370
Jankowska, A. M., Szpurka, H., Tiu, R. V., Makishima, H., Afable, M., Huh, J., O'Keefe, C. L., Ganetzky, R., McDevitt, M. A., & Maciejewski, J. P. (2009) · Blood · doi:10.1182/blood-2009-02-205690 · Cited by 331
Jankowska, A. M., Makishima, H., Tiu, R. V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311019 · Cited by 330
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404863 · Cited by 311
Self-citationDunbar, A. J., Gondek, L. P., O'Keefe, C. L., Makishima, H., Rataul, M. S., Szpurka, H., Sekeres, M. A., Wang, X. F., McDevitt, M. A., & Maciejewski, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2754 · Cited by 299
Kohlmann, A., Grossmann, V., Klein, H.-U., Schindela, S., Weiss, T., Kazak, B., Dicker, F., Schnittger, S., Dugas, M., Kern, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1361 · Cited by 299
Self-citationGelsi-Boyer, V., Brecqueville, M., Devillier, R., Murati, A., Mozziconacci, M.-J., & Birnbaum, D. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-12 · Cited by 278
Self-citationClonal architecture of chronic myelomonocytic leukemias
Itzykson, R., Kosmider, O., Renneville, A., Morabito, M., Preudhomme, C., Berthon, C., Adès, L., Fenaux, P., Platzbecker, U., Gagey, O., et al. (2013) · Blood · doi:10.1182/blood-2012-06-440347 · Cited by 276
Self-citationCytogenetic risk stratification in chronic myelomonocytic leukemia
Such, E., Cervera, J., Costa, D., Sole, F., Vallespi, T., Luno, E., Collado, R., Calasanz, M. J., Hernandez-Rivas, J. M., Cigudosa, J. C., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030957 · Cited by 269
A novel hierarchical prognostic model of AML solely based on molecular mutations
Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C.-M., Staib, P., Serve, H., et al. (2012) · Blood · doi:10.1182/blood-2012-03-419622 · Cited by 252
Self-citationKosmider, O., Gelsi-Boyer, V, Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Hunault-Berger, M., Slama, B., Vey, N., Lacombe, C., et al. (2010) · Leukemia · doi:10.1038/leu.2010.52 · Cited by 247
Self-citationTET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
Kosmider, O., Gelsi-Boyer, V., Ciudad, M., Racoeur, C., Jooste, V., Vey, N., Quesnel, B., Fenaux, P., Bastie, J.-N., Beyne-Rauzy, O., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.011205 · Cited by 247
Self-citationDamm, F., Kosmider, O., Gelsi-Boyer, V., Renneville, A., Carbuccia, N., Hidalgo-Curtis, C., Della Valle, V., Couronné, L., Scourzic, L., Chesnais, V., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400994 · Cited by 231
Self-citationAbdel-Wahab, O., Pardanani, A., Patel, J., Wadleigh, M., Lasho, T., Heguy, A., Beran, M., Gilliland, D. G., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.58 · Cited by 231
Lee, B. H., Tothova, Z., Levine, R. L., Anderson, K., Buza-Vidas, N., Cullen, D. E., McDowell, E. P., Adelsperger, J., Fröhling, S., Huntly, B. J. P., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.031 · Cited by 230
Smith, A. E., Mohamedali, A. M., Kulasekararaj, A., Lim, Z., Gäken, J., Lea, N. C., Przychodzen, B., Mian, S. A., Nasser, E. E., Shooter, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-274704 · Cited by 224
Gelsi‐Boyer, V., Trouplin, V., Roquain, J., Adélaïde, J., Carbuccia, N., Esterni, B., Finetti, P., Murati, A., Arnoulet, C., Zerazhi, H., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08381.x · Cited by 222
Self-citationMakishima, H., Cazzolli, H., Szpurka, H., Dunbar, A., Tiu, R., Huh, J., Muramatsu, H., O'Keefe, C., Hsi, E., Paquette, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7503 · Cited by 218
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
Padua, R., Guinn, B.-A., Al-Sabah, A., Smith, M., Taylor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401044 · Cited by 213
Chen, C., & George, S. L. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040107 · Cited by 202
Braun, T., Itzykson, R., Renneville, A., de Renzis, B., Dreyfus, F., Laribi, K., Bouabdallah, K., Vey, N., Toma, A., Recher, C., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352039 · Cited by 200
Self-citationKuo, M.-C., Liang, D.-C., Huang, C.-F., Shih, Y.-S., Jh, W., Lin, T.-L., & Shih, L.-Y. (2009) · Leukemia · doi:10.1038/leu.2009.48 · Cited by 174
Schanz, J., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A., Aul, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3978 · Cited by 160
Großmann, V., Kohlmann, A., Eder, C., Haferlach, C., Kern, W., Cross, N. C. P., Haferlach, T., & Schnittger, S. (2011) · Leukemia · doi:10.1038/leu.2011.10 · Cited by 150
Self-citationGenome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Rémy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires‐Alj, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-299 · Cited by 147
Self-citationActivity of azacitidine in chronic myelomonocytic leukemia
Costa, R., Abdulhaq, H., Haq, B., Shadduck, R. K., Latsko, J. M., Zenati, M. S., Atem, F., Rossetti, J. M., Sahovic, E., & LISTER, J. W. (2010) · Cancer · doi:10.1002/cncr.25759 · Cited by 141
Renneville, A., Boissel, N., Nibourel, O., Berthon, C., Hélevaut, N., Gardin, C., Cayuela, J., Hayette, S., Reman, O., Contentin, N., et al. (2012) · Leukemia · doi:10.1038/leu.2011.382 · Cited by 139
Self-citationTyner, J. W., Erickson, H., Deininger, M. W., Willis, S. G., Eide, C. A., Levine, R. L., Heinrich, M. C., Gattermann, N., Gilliland, D. G., Druker, B. J., et al. (2008) · Blood · doi:10.1182/blood-2008-04-152157 · Cited by 137
Risk Assessment in Chronic Myelomonocytic Leukemia (CMML)
Germing, U., Kündgen, A., & Gattermann, N. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819042000207271 · Cited by 135
Abdel-Wahab, O., Pardanani, A., Rampal, R., Lasho, T. L., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.82 · Cited by 134
Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
Wijermans, P., Rüter, B. H., Baer, M. R., Slack, J. L., Saba, H. I., & Lübbert, M. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.08.004 · Cited by 129
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
Aribi, A. M., Borthakur, G. M., Ravandi, F., Shan, J., Davisson, J., Cortes, J. E., & Kantarjian, H. M. (2007) · Cancer · doi:10.1002/cncr.22457 · Cited by 128
Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases.
Fenaux, P., Beuscart, R., Laı̈, J. L., Jouet, J. P., & Bauters, F. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.9.1417 · Cited by 124
Self-citationKar, S. A., Jankowska, A., Makishima, H., Visconte, V., Jerez, A., Sugimoto, Y., Muramatsu, H., Traina, F., Afable, M. G., Guinta, K. M., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.064048 · Cited by 88
Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia
Bacher, U., Haferlach, T., Schnittger, S., Kreipe, H. H., & Kröger, N. M. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08631.x · Cited by 62
Self-citationC‐terminal nucleophosmin mutations are uncommon in chronic myeloid disorders
Caudill, J. S. C., Sternberg, A. J., Li, C., Tefferi, A., Lasho, T. L., & Steensma, D. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06081.x · Cited by 49
Current status of allogeneic HST for chronic myelomonocytic leukemia
Cheng, H., Kirtani, V., & Gergis, U. S. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.141 · Cited by 32
Statistical analysis of proliferative index data in clinical trials
Grambsch, P. M., Louis, T. A., Bostick, R. M., Grandits, G., Fosdick, L., Darif, M., & Potter, J. D. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131603 · Cited by 27
Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS
Traina, F., Jankowska, A. M., Visconte, V., Sugimoto, Y., Szpurka, H., Makishima, H., Jerez, A., O’Keefe, C. L., Sekeres, M. A., Advani, A. S., et al. (2011) · Blood · doi:10.1182/blood.v118.21.461.461 · Cited by 27
Harrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Cited by
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Arber, D. A., Orazi, A., Hasserjian, R. P., Borowitz, M. J., Calvo, K. R., Kvasnicka, H.-M., Wang, S. A., Bagg, A., Barbui, T., Branford, S., et al. (2022) · Blood · doi:10.1182/blood.2022015850 · Cited by 2,945
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Alternative splicing and cancer: a systematic review
Zhang, Y., Qian, J., Gu, C., & Yang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00486-7 · Cited by 497
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 379
Self-citation
Metadata
- Authors
- Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., Vey, N., Braun, T., Haferlach, T., Dreyfus, F., Cross, N. C. P., Preudhomme, C., Bernard, O. A., Fontenay, M., Vainchenker, W., Schnittger, S., Birnbaum, D., Droin, N., & Solary, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-07-01
- Volume
- 31
- Issue
- 19
- Pages
- 2428-2436
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149089431
- Cited by
- 545
- References
- 60
- FWCI
- 36.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.